Trending NewsTrending NewsNASDAQ:TARA Protara Therapeutics (TARA) Stock Price, News & Analysis $2.62 +0.19 (+7.82%) Closing price 04:00 PM EasternExtended Trading$2.59 -0.03 (-1.07%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Protara Therapeutics Stock (NASDAQ:TARA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Protara Therapeutics alerts:Sign Up Key Stats Today's Range$2.40▼$2.7050-Day Range$2.13▼$3.9752-Week Range$2.09▼$7.82Volume765,032 shsAverage Volume910,273 shsMarket Capitalization$161.31 millionP/E RatioN/ADividend YieldN/APrice Target$26.25Consensus RatingModerate Buy Company Overview Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer. Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications. The company’s development programs are centered on advancing novel therapies through clinical testing and, if successful, obtaining regulatory approval for use in appropriate patient populations. The company was formed through the combination of ArTara Therapeutics and Protara Therapeutics and began trading under the Protara name in 2020. Protara is headquartered in New York and conducts its research and clinical development activities through collaborations and studies in the United States. Jesse Shefferman serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Protara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreTARA MarketRank™: 3.10913373462 of 5 starsProtara Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 349th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingProtara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialProtara Therapeutics has a consensus price target of $26.25, representing about 898.1% upside from its current price of $2.63.Amount of Analyst CoverageProtara Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Protara Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protara Therapeutics are expected to decrease in the coming year, from ($1.40) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protara Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protara Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtara Therapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.93% of the float of Protara Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtara Therapeutics has a short interest ratio ("days to cover") of 2.87, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protara Therapeutics has recently decreased by 46.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtara Therapeutics does not currently pay a dividend.Dividend GrowthProtara Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.87 News SentimentProtara Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Protara Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for TARA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Protara Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.60% of the stock of Protara Therapeutics is held by insiders.Percentage Held by Institutions38.13% of the stock of Protara Therapeutics is held by institutions.Read more about Protara Therapeutics' insider trading history. Receive TARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TARA Stock News HeadlinesProtara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMProtara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business UpdateNovember 6, 2026 | globenewswire.comDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.November 11 at 1:00 AM | TradeWins (Ad)Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on ...October 15, 2026 | finance.yahoo.comProtara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral SupportOctober 15, 2026 | globenewswire.comProtara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | globenewswire.comProtara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should WatchAugust 21, 2026 | tipranks.comProtara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business UpdateAugust 12, 2026 | markets.businessinsider.comSee More Headlines TARA Stock Analysis - Frequently Asked Questions How have TARA shares performed this year? Protara Therapeutics' stock was trading at $5.33 at the beginning of the year. Since then, TARA shares have decreased by 50.7% and is now trading at $2.63. How were Protara Therapeutics' earnings last quarter? Protara Therapeutics, Inc. (NASDAQ:TARA) issued its quarterly earnings results on Friday, November, 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.02. When did Protara Therapeutics IPO? Protara Therapeutics (TARA) raised $79 million in an initial public offering (IPO) on Wednesday, October 22nd 2014. The company issued 6,110,000 shares at $12.00-$14.00 per share. Who are Protara Therapeutics' major shareholders? Protara Therapeutics' top institutional investors include Oppenheimer & Co. Inc. (0.37%), Cibc World Market Inc. (0.26%), Fisher Asset Management LLC (0.22%) and Alps Advisors Inc. (0.13%). Insiders that own company stock include Jacqueline Zummo, Jacqueline Zummo and Opaleye Management Inc. View institutional ownership trends. How do I buy shares of Protara Therapeutics? Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protara Therapeutics investors own include Iovance Biotherapeutics (IOVA), Viking Therapeutics (VKTX), Alibaba Group (BABA), Pfizer (PFE), Definium Therapeutics (DFTX), Intel (INTC) and FuelCell Energy (FCEL). Company Calendar Last Earnings11/06/2026Today11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TARA's financial health is in the Red zone, according to TradeSmith. TARA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TARA Previous SymbolNASDAQ:PRTO CIK1359931 Webwww.protaratx.com Phone(646) 844-0337Fax781-487-6729Employees51Year Founded2017Price Target and Rating Average Price Target for Protara Therapeutics$26.25 High Price Target$28.00 Low Price Target$24.00 Potential Upside/Downside+901.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-46.15% Return on Assets-42.75% Debt Debt-to-Equity RatioN/A Current Ratio9.01 Quick Ratio10.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.29 per share Price / Book1.14Miscellaneous Outstanding Shares61,570,000Free Float54,604,000Market Cap$161.31 million OptionableOptionable Beta1.54 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:TARA) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARA Stock Alerts